临床并发症增加,冠状病毒治疗竞赛成为现实

2020-10-14 09:25

Race for coronavirus cure hits reality as clinic complications mount lJm世界播

临床并发症增加,冠状病毒治疗竞赛成为现实lJm世界播


暂无lJm世界播

The need to find viable treatments and ways to arrest the spread of the virus is becoming more pressing. lJm世界播

找到可行的治疗方法和方法来阻止病毒的传播变得更加紧迫lJm世界播


WASHINGTON (BLOOMBERG) - The sprint to find medical breakthroughs to contain Covid-19 stumbled this week, as a pair of pharmaceutical giants working to develop treatments and vaccines suffered setbacks in the clinic. lJm世界播

华盛顿(彭博社)-本周,寻找医学突破以遏制新冠肺炎的冲刺行动受挫,两家致力于开发治疗和疫苗的制药巨头在诊所遭遇挫折。lJm世界播


On Tuesday, Eli Lilly & Co. said that enrolment in a government-sponsored clinical trial of its antibody therapy had been paused out of safety concerns. That came less than 24 hours after Johnson & Johnson said research on its experimental vaccine was paused after a study volunteer fell ill. lJm世界播

周二,礼来公司(Eli Lilly&Co.)表示,出于安全考虑,政府资助的抗体疗法临床试验的注册已经暂停。不到24小时前,强生公司表示,在一名研究志愿者生病后,暂停了对其实验疫苗的研究。lJm世界播


The developments are likely to heighten worry that the pursuit of products to prevent and treat infections is moving too quickly. lJm世界播

这些进展可能会加剧人们的担忧,即人们对预防和治疗感染的产品的追求进展太快了。lJm世界播


Regulators and drugmakers have faced questions about whether political pressure was overwhelming scientific rigour ahead of the presidential election on Nov 3. lJm世界播

监管机构和制药商一直面临着这样的问题:在11月3日的总统选举之前,政治压力是否压倒了科学的严谨性。lJm世界播


Last week, President Donald Trump, trailing in the polls, touted antibody treatments as a cure, and his administration has pushed hard for the rapid approval of the treatments and a vaccine. lJm世界播

上周,在民调中落后的唐纳德·特朗普(Donald Trump)总统吹捧抗体疗法是一种治愈方法,他的政府一直在努力推动这些疗法和疫苗的迅速批准。lJm世界播


However, the trial complications are happening in an environment of intense scrutiny, executives and industry observers said, and the highly public nature of the hunt for vaccines and treatments is magnifying events that in other studies would be considered routine. lJm世界播

然而,高管和行业观察人士表示,试验并发症是在严格审查的环境中发生的,寻找疫苗和治疗的高度公开性质正在放大在其他研究中被认为是例行公事的事件。lJm世界播


"I'm not surprised at all that these pauses are happening. Where I would be surprised is if they weren't happening," said Greg Poland, director of the Vaccine Research Group at the Mayo Clinic in Rochester, Minnesota. lJm世界播

明尼苏达州罗切斯特市梅奥诊所疫苗研究小组主任格雷格·波兰(Greg Poll)说,“我对这些暂停的发生一点都不感到惊讶。如果它们没有发生,我会感到惊讶。”lJm世界播


The US has poured nearly US$18 billion (S$24.4 billion) into Operation Warp Speed, its programme designed to hasten the development of virus drugs and inoculations. lJm世界播

美国已经向“翘曲速度行动”投入了近180亿美元(244亿新元),该计划旨在加速病毒药物和疫苗的开发。lJm世界播


Companies have been moving at unprecedented speeds to develop complex and innovative products for a virus that has killed more than 215,000 Americans. lJm世界播

公司一直在以前所未有的速度为这种已导致超过21.5万美国人死亡的病毒开发复杂而创新的产品。lJm世界播


The need to find viable treatments and ways to arrest the spread of the virus is becoming more pressing. lJm世界播

找到可行的治疗方法和方法来阻止病毒的传播变得更加紧迫。lJm世界播


Cases are climbing again in the US and Europe ahead of what public-health officials have warned could become a dangerous winter with Covid-19 circulating unchecked alongside seasonal influenza. lJm世界播

美国和欧洲的病例再次攀升,公共卫生官员警告说,新冠肺炎与季节性流感一起肆无忌惮地传播,可能会成为一个危险的冬天。lJm世界播


More virulent outbreaks could spur the need for more economically damaging infection-control measures. lJm世界播

更致命的疫情可能会刺激对更具经济破坏性的感染控制措施的需求。lJm世界播


J&J's vaccine was considered one of the frontrunners in the race for an inoculation. Along with rival shots made by Pfizer Inc. and partner BioNTech SE, Moderna Inc., and AstraZeneca Plc and the University of Oxford, its safety and effectiveness is being studied in a large trial. lJm世界播

强生的疫苗被认为是接种竞争中的领跑者之一。以及辉瑞公司(Pfizer Inc.)制造的竞争对手的疫苗。与合作伙伴BioNTech SE、现代公司、阿斯利康公司和牛津大学合作,其安全性和有效性正在进行大规模试验研究。lJm世界播


Hope for the shot's effectiveness has been high, since it is expected to be delivered in a single dose. Some rival shots will require a second injection. lJm世界播

人们对注射的有效性抱有很高的希望,因为预计只需一剂就能注射。一些竞争对手的疫苗将需要第二次注射。lJm世界播


J&J Chief Financial Officer Joseph Wolk said in an interview the company doesn't know whether the person who was sickened had received the vaccine or a placebo. lJm世界播

强生首席财务长约瑟夫·沃尔克(Joseph Wolk)在接受采访时说,公司不知道患病的人是否接种了疫苗或安慰剂。lJm世界播


He said that J&J is sticking to its development time-line and plans to be able to produce 1 billion doses a year. lJm世界播

他说,强生正在坚持其开发时间表,计划每年能够生产10亿剂。lJm世界播


"Everybody is anxious to get a vaccine to the pandemic, for the right reasons," Wolk said, "but nobody is cutting corners or suggesting that there be undue pressure to make that happen." lJm世界播

沃尔克说:“出于正确的理由,每个人都急于获得大流行的疫苗,但没有人偷工减料,也没有人暗示有不必要的压力来实现这一目标。”lJm世界播


The stakes in a vaccine trial are especially high, since inoculations are given to people of all ages, many of whom are otherwise healthy. lJm世界播

疫苗试验的风险特别高,因为疫苗接种适用于所有年龄段的人,其中许多人在其他方面都很健康。lJm世界播


Poland, of the Mayo Clinic, said he had never seen a vaccine trial under as much scrutiny as the Covid-19 trials. lJm世界播

梅奥诊所的波兰人说,他从来没有见过像新冠肺炎试验这样受到如此严格审查的疫苗试验。lJm世界播


"No one wants to misstep here," he said. "The decisions we are making will affect our children, our parents, our families. We aren't making decisions in a void." lJm世界播

“没有人想在这里失足,”他说。“我们正在做的决定将影响我们的孩子、我们的父母、我们的家庭。我们不是凭空做出决定的。”lJm世界播


Wall Street analysts who follow the drug industry said pauses are a common feature of clinical trials, and earlier data on J&J's vaccine and Lilly's antibody treatment had been encouraging. lJm世界播

跟踪制药业的华尔街分析师表示,暂停是临床试验的常见特征,早先有关强生疫苗和礼来公司抗体治疗的数据一直令人鼓舞。lJm世界播


"Trial halts are fairly common, and although we don't know the exact reason for this stop, the majority of safety incidents aren't usually related to the vaccine," Shore Capital analyst Adam Barker wrote in a note about J&J's temporary halt. lJm世界播

Shore Capital分析师亚当·巴克(Adam Barker)在一份关于强生暂停试验的报告中写道:“试验暂停是相当常见的,尽管我们不知道停止试验的确切原因,但大多数安全事件通常与疫苗无关,”Shore Capital分析师亚当·巴克(Adam Barker)在一份关于强生暂停试验的报告中写道。lJm世界播


J&J shares declined 2.2 per cent on Tuesday to lose at US$148.36 at 4pm in New York. Eli Lilly shares ended the day down 2.9 per cent at US$150.08. lJm世界播

周二纽约下午4点,强生股价下跌2.2%,至148.36美元。礼来公司股价当天收盘下跌2.9%,至150.08美元。lJm世界播


Presidential Push Lilly's drug is part of a promising class of therapies known as monoclonal antibodies, which top US infectious-disease expert Anthony Fauci has called a bridge to a vaccine. lJm世界播

总统推动礼来公司的药物是一种被称为单克隆抗体的有前途的疗法的一部分,美国顶级传染病专家安东尼·福奇(Anthony Fuci)称这种疗法是通往疫苗的桥梁。lJm世界播


Last week, the company asked the US Food and Drug Administration to grant it an emergency-use authorisation after data from earlier studies showed the drug could reduce hospitalisations. lJm世界播

上周,该公司要求美国食品和药物管理局(US Food And Drug Administration)批准其紧急使用,此前来自早期研究的数据显示,该药物可以减少住院人数。lJm世界播


The National Institutes of Health is testing Lilly's treatment in Covid-19 patients in and out of the hospital. Preliminary data from the trial, known as Activ-3, isn't yet available. Lilly is developing its antibody with Canadian biotechnology company AbCellera Biologics Inc. lJm世界播

美国国立卫生研究院正在测试礼来公司在医院内外对新冠肺炎患者的治疗。这项名为Activ-3的试验的初步数据尚未公布。礼来公司正在与加拿大生物技术公司AbCellera Biologics Inc.合作开发其抗体。lJm世界播


The treatment is similar to one being developed by Regeneron Pharmaceuticals Inc. that was given to Trump after he tested positive for coronavirus. He credited the Regeneron drug for his recovery and vowed to make it and Lilly's treatment widely accessible. lJm世界播

这种疗法类似于Regeneron制药公司正在开发的一种疗法。这是在特朗普冠状病毒检测呈阳性后给他的。他将Regeneron药物归功于他的康复,并誓言要让它和莉莉的治疗更广泛地获得。lJm世界播


Trump's illness and his endorsement of antibody drugs have put a spotlight on the two therapies, which prior to his stint in the hospital had taken a back seat to vaccines in the public eye. As the campaign intensifies in its final weeks, and Covid-19 case counts rise, drugs like Lilly's will be increasingly at centre of attention. lJm世界播

特朗普的疾病和他对抗体药物的支持让这两种疗法成为人们关注的焦点,在他入院之前,这两种疗法在公众眼中的地位低于疫苗。随着这场运动在最后几周的加剧,以及新冠肺炎案件数量的增加,像礼来公司这样的药物将越来越成为人们关注的中心。lJm世界播


"Normally this stuff never makes the news," said the Mayo Clinic's Poland. "This is under a microscope and every sneeze and hiccup gets reported." lJm世界播

“通常这些东西从来不会成为新闻,”梅奥诊所的波兰人说。“这是在显微镜下进行的,每次打喷嚏和打嗝都会被报告。”lJm世界播

© 2016 世界播 www.shijiebobao.com 中国互联网举报中心 京ICP证140141号 鄂ICP备18018000号-1
违法和不良信息举报: